Allogene Therapeutics Faces Potential Risk as Cellectis Hit with Patent Infringement Lawsuit Over TALEN Gene-Editing Technology
Reuters
Oct 14
Allogene <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Potential Risk as Cellectis Hit with Patent Infringement Lawsuit Over TALEN Gene-Editing Technology
Allogene Therapeutics Inc. disclosed that Factor Bioscience Inc. has filed a complaint in the United States District Court for the District of Delaware against Cellectis S.A. and its affiliate, alleging infringement of three U.S. patents related to gene-editing techniques. The complaint claims that Cellectis's TALEN-based gene-editing technology, which Allogene licenses for use in developing its allogeneic CAR T cell product candidates, infringes Factor's patented mRNA TALEN technology. AstraZeneca and certain affiliates are also named as defendants in the lawsuit for direct infringement. While Allogene is not currently a party to the litigation, it relies on the disputed technology for key products and could face future claims as a commercial user. Cellectis has informed Allogene of its intent to vigorously defend against Factor's allegations. The situation poses intellectual property risks for Allogene, as outlined in its recent SEC filings.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-044828), on October 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.